Latest DNA vaccination Stories
BLUE BELL, Pa., Nov. 14, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania (UPenn), adding worldwide rights to technology and intellectual property for novel synthetic vaccines against cancer, infectious diseases and potential biodefense pathogens. These technologies were developed by UPenn Professor David B. Weiner and collaborators. Dr. Weiner is a pioneer in the field of DNA vaccines,...
BLUE BELL, Pa., Nov. 12, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its synthetic hepatitis B (HBV) therapeutic vaccine generated strong T cell responses that eliminated targeted liver cells in mice. This data points to the DNA vaccine's potential to clear HBV infection and thereby prevent liver cancer in humans, an encouraging development given that nearly one-third of the world's population is infected with hepatitis B, with 400 million...
Connie K. Ho for redOrbit.com – Your Universe Online Researchers from Arizona State University (ASU) recently revealed novel technology that could help protect against a number of pathogens at lower costs and with improved methods. A re-engineered bacterium that can quicken the delivery of the DNA vaccines to host cells, the new platform was found to provide complete protection against influenza in mice. The team of investigators believes that the new technique could be manufactured...
Certain immune cell receptors are more common than mere chance would dictate. New research shows why Our immune system must be tremendously complex to respond to the unending assault of viruses, bacteria and cancerous cells. One of the mechanisms used by the immune system to cope with the huge variety of possible threats is to randomly combine DNA segments for the production of receptors on lymphocytes – a type of white blood cell. The number of possible receptors that can be produced in...
BLUE BELL, Pa., Oct. 15, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its majority-owned subsidiary, VGX Animal Health, has received approval to market LifeTide® SW 5.0, the world's first approved growth hormone releasing hormone (GHRH) therapy for food animals, in New Zealand. LifeTide is a once-in-a-lifetime treatment for female pigs (sows) that has demonstrated significant decreases in perinatal mortality of piglets from treated sows...
BLUE BELL, Pa., Oct. 5, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has been named Best Mid-Stage Product Development Company by the Philadelphia Business Journal as part of the Journal's Life Sciences Awards, an annual program recognizing the region's "medical miracle makers for their innovative approaches to improving the delivery of health care." An independent panel of judges from leading companies and universities in the state selected the finalists....
BLUE BELL, Pa., Oct. 4, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today the publication of positive immunological effects in preclinical animal models of optimized electroporation (EP) parameters for its minimally invasive skin (intradermal) EP delivery devices in the peer-reviewed journal, Human Gene Therapy. The newly published optimized conditions for Inovio's skin EP delivery systems will dramatically enhance this delivery system as an...
BLUE BELL, Pa., Sept. 18, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that J. Joseph Kim, Ph.D., President and CEO, will present and participate in a panel at BIOX, Noble Financial Capital Markets' Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus on September 24-25, 2012. Inovio PresentationMonday, September 243:00 PM ET Panel PresentationMonday, September 245:55 PM ET"Innovation in Immunotherapy &...
THE WOODLANDS, Texas, Sept. 17, 2012 /PRNewswire/ -- VGX Animal Health, a majority-owned subsidiary of Inovio Pharmaceuticals (NYSE MKT: INO), announced today that a study published in a leading peer-reviewed journal showed that LifeTide® SW 1.0, an optimized version requiring only 20% of the dose of the licensed LifeTide® SW 5.0, demonstrated significant decreases in perinatal mortality rate, an increase in the number of pigs born alive, and an increase in the weight and number...
BLUE BELL, Pa., Aug. 27, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that senior executives of Inovio will present overviews of the company at the Stifel Nicolaus Healthcare Conference, Liolios Group Gateway Conference, and the Rodman & Renshaw Global Investment Conference. Stifel Nicolaus Healthcare ConferenceSeptember 5-6200 Boylston Street, Four Seasons HotelBoston, MA Inovio PresentationThursday, September 63:50 - 4:20 PM ETJ. Joseph...
